Impax Laboratories (IPXL) Earns Media Impact Rating of 0.26

Press coverage about Impax Laboratories (NASDAQ:IPXL) has trended positive this week, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Impax Laboratories earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 45.3691973775553 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

A number of equities research analysts have recently issued reports on the company. Cantor Fitzgerald boosted their price objective on Impax Laboratories from $20.00 to $25.00 and gave the stock an “overweight” rating in a report on Monday, September 11th. Piper Jaffray Companies restated a “hold” rating and set a $17.00 price objective on shares of Impax Laboratories in a report on Sunday. Canaccord Genuity assumed coverage on Impax Laboratories in a report on Monday, July 31st. They set a “hold” rating and a $19.00 price objective for the company. Zacks Investment Research cut Impax Laboratories from a “hold” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, Deutsche Bank AG set a $21.00 price objective on Impax Laboratories and gave the stock a “buy” rating in a report on Monday, July 17th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the company. Impax Laboratories presently has a consensus rating of “Hold” and a consensus target price of $18.16.

Shares of Impax Laboratories (IPXL) traded down 3.48% on Friday, reaching $20.80. 1,702,183 shares of the company’s stock traded hands. Impax Laboratories has a one year low of $7.75 and a one year high of $27.29. The company’s 50-day moving average price is $19.04 and its 200 day moving average price is $15.40. The firm’s market cap is $1.55 billion.

Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.04. The company had revenue of $202.08 million during the quarter, compared to the consensus estimate of $195.62 million. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. Impax Laboratories’s revenue for the quarter was up 17.1% on a year-over-year basis. During the same period last year, the firm earned $0.21 EPS. On average, equities analysts forecast that Impax Laboratories will post $0.70 EPS for the current fiscal year.

WARNING: “Impax Laboratories (IPXL) Earns Media Impact Rating of 0.26” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://ledgergazette.com/2017/09/17/impax-laboratories-ipxl-earns-media-impact-rating-of-0-26.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Insider Buying and Selling by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply